Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference


Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.

A live audio webcast of the presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for at least 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly-differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual adenosine A2a/A2b receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple negative breast and renal cell cancers. AB680, the first CD73 small-molecule inhibitor in the clinic, is in Phase 1/1b development for the treatment of first-line metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus's anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences


These press releases may also interest you

at 01:55
Cellcom Israel Ltd. (the "Company") announced today that following the previously reported approval of the court to the sale of the controlling stake in Discount Investment Corporation Ltd. ? the Company's indirect controlling shareholder -  to a...

at 01:42
Kahoot!, the global learning platform company, today announced the acquisition of Drops, one of the fastest growing language platforms in the world. Through this acquisition, Kahoot! plans to further expand its platform and make language learning...

at 01:25
Mydecine Innovations Group Inc. (the "Company") announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month periods ended March 31, 2020 and June 30, 2020, any corresponding...

at 01:24
With their ability to transport electricity without loss and at zero resistance, superconductors are a technology that could solve a host of environmental and energy problems. The Nano Frontier Superconducting Materials Group at MANA, led by Prof....

at 01:15
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases 18-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with...

at 01:00
With online threats originating from across the world and on all levels of the internet only increasing, the need to remain dynamic and neutralize attacks before any damage can be done is paramount. The key to threat intelligence solutions is to...



News published on 12 february 2020 at 16:15 and distributed by: